risks of microdosing glp 1 GLP-1s: Does It Work? and Benefits Microdosing GLP-1s: Risks & Considerations
Description
Decide, together with your prescribing clinician, whether holding a dose is appropriate in your particular situation
Although the medication caused localized and nonserious reactions, there were no symptoms such as large nodules or indurations
These substances represent an evolving category where new compounds continue to emerge
The REWIND trial investigated the cardiovascular benefits of dulaglutide, a GLP-1 receptor agonist, in a population of 9,901 patients with T2DM aged 50+ and either established CVD or risk factors
Restless legs syndrome/WillisEkbom disease and pregnancy
European Medicines Agency, 2024)
